{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015149","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.379493+00:00","generated_at":"2026-05-30T02:03:12.241837+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Scholar Rock Phase 3 SAPPHIRE trial meets primary endpoint; Q3 net loss $64.5M","bullets":["Phase 3 SAPPHIRE achieved primary endpoint: apitegromab 1.8-point HFMSE improvement (p=0.0192) vs placebo.","Plans to submit BLA and MAA for apitegromab in SMA in Q1 2025.","Phase 2 EMBRAZE trial (apitegromab + GLP-1 for obesity) fully enrolled; data expected Q2 2025.","Completed upsized $345M public offering; proforma cash $463.5M extends runway into Q4 2026.","Q3 2024 net loss $64.5M ($0.66/share) vs $42.4M ($0.53/share) in Q3 2023; no revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015149","json":"https://secwatch.observer/filing/0001558370-24-015149.json","markdown":"https://secwatch.observer/filing/0001558370-24-015149.md","text":"https://secwatch.observer/filing/0001558370-24-015149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/0001558370-24-015149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:03:12.241837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}